AU2016309337B2 - Hydroxytriazine compound and medical use thereof - Google Patents
Hydroxytriazine compound and medical use thereof Download PDFInfo
- Publication number
- AU2016309337B2 AU2016309337B2 AU2016309337A AU2016309337A AU2016309337B2 AU 2016309337 B2 AU2016309337 B2 AU 2016309337B2 AU 2016309337 A AU2016309337 A AU 2016309337A AU 2016309337 A AU2016309337 A AU 2016309337A AU 2016309337 B2 AU2016309337 B2 AU 2016309337B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- mixture
- pharmaceutically acceptable
- acceptable salt
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015160284 | 2015-08-17 | ||
| JP2015-160284 | 2015-08-17 | ||
| PCT/JP2016/073879 WO2017030115A1 (ja) | 2015-08-17 | 2016-08-16 | ヒドロキシトリアジン化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016309337A1 AU2016309337A1 (en) | 2018-02-01 |
| AU2016309337B2 true AU2016309337B2 (en) | 2021-03-04 |
Family
ID=58052084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016309337A Ceased AU2016309337B2 (en) | 2015-08-17 | 2016-08-16 | Hydroxytriazine compound and medical use thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20170057943A1 (enExample) |
| EP (2) | EP3339296A4 (enExample) |
| JP (4) | JP2017039714A (enExample) |
| KR (1) | KR20180037270A (enExample) |
| CN (1) | CN108137515B (enExample) |
| AR (1) | AR105711A1 (enExample) |
| AU (1) | AU2016309337B2 (enExample) |
| BR (1) | BR112018001809A2 (enExample) |
| CA (1) | CA2992410A1 (enExample) |
| CL (1) | CL2018000430A1 (enExample) |
| CO (1) | CO2018002516A2 (enExample) |
| IL (1) | IL257559B (enExample) |
| MX (1) | MX375283B (enExample) |
| PE (1) | PE20180951A1 (enExample) |
| PH (1) | PH12018500181A1 (enExample) |
| SG (1) | SG11201800698VA (enExample) |
| TW (1) | TWI704139B (enExample) |
| WO (1) | WO2017030115A1 (enExample) |
| ZA (1) | ZA201801134B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| TWI704139B (zh) * | 2015-08-17 | 2020-09-11 | 日商日本煙草產業股份有限公司 | 羥基三化合物及其醫藥用途 |
| EP3372589B1 (en) * | 2015-10-29 | 2021-10-20 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| RU2648181C1 (ru) * | 2017-05-25 | 2018-03-22 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения нейроретинопатии вследствие тяжелой преэклампсии |
| EP3645527A1 (de) * | 2017-06-26 | 2020-05-06 | Merck Patent GmbH | Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen |
| US20250340557A1 (en) * | 2022-07-06 | 2025-11-06 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| EP2383262A1 (en) * | 2008-12-10 | 2011-11-02 | Topharman Shanghai Co., Ltd. | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2015125842A1 (ja) * | 2014-02-20 | 2015-08-27 | 日本たばこ産業株式会社 | トリアジン化合物及びその医薬用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH473818A (de) | 1964-03-18 | 1969-06-15 | Ciba Geigy | Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung |
| SU1313854A1 (ru) | 1985-04-17 | 1987-05-30 | Институт Органической Химии Ан Армсср | Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина |
| DE19543730A1 (de) | 1995-11-23 | 1997-05-28 | Ciba Geigy Ag | Bis-Resorcinyl-Triazine |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| ZA9710727B (en) | 1996-12-05 | 1998-06-12 | Amgen Inc | Substituted pyrimidine compounds and methods of use. |
| AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| CA2366858A1 (en) | 1999-04-01 | 2000-10-12 | Margaret Yuhua Chu-Moyer | Sorbitol dehydrogenase inhibitors |
| JP5580732B2 (ja) | 2007-04-03 | 2014-08-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 置換ベンゼン殺菌・殺カビ剤 |
| JP5388270B2 (ja) | 2008-06-04 | 2014-01-15 | 株式会社Ａｄｅｋａ | ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法 |
| BRPI0913343B1 (pt) | 2008-06-04 | 2018-01-23 | Adeka Corporation | Método para produção do composto 2,4,6-tri (hidroxifenil)-1,3,5-triazina |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| JP5579862B2 (ja) | 2009-10-23 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミクロソームプロスタグランジンｅ２シンターゼ−１のインヒビター |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| FR2983859B1 (fr) | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
| CA2873984A1 (en) | 2012-05-23 | 2013-11-28 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| CN105586773A (zh) | 2014-11-13 | 2016-05-18 | 东丽纤维研究所（中国）有限公司 | 一种拒水抗紫外纺织品及其生产方法和用途 |
| TWI704139B (zh) * | 2015-08-17 | 2020-09-11 | 日商日本煙草產業股份有限公司 | 羥基三化合物及其醫藥用途 |
-
2016
- 2016-08-16 TW TW105126071A patent/TWI704139B/zh not_active IP Right Cessation
- 2016-08-16 PE PE2018000185A patent/PE20180951A1/es unknown
- 2016-08-16 BR BR112018001809-0A patent/BR112018001809A2/pt not_active Application Discontinuation
- 2016-08-16 KR KR1020187007349A patent/KR20180037270A/ko not_active Ceased
- 2016-08-16 AU AU2016309337A patent/AU2016309337B2/en not_active Ceased
- 2016-08-16 CA CA2992410A patent/CA2992410A1/en active Pending
- 2016-08-16 CN CN201680060597.6A patent/CN108137515B/zh active Active
- 2016-08-16 US US15/237,763 patent/US20170057943A1/en not_active Abandoned
- 2016-08-16 EP EP16837104.5A patent/EP3339296A4/en not_active Withdrawn
- 2016-08-16 WO PCT/JP2016/073879 patent/WO2017030115A1/ja not_active Ceased
- 2016-08-16 SG SG11201800698VA patent/SG11201800698VA/en unknown
- 2016-08-16 MX MX2018002044A patent/MX375283B/es active IP Right Grant
- 2016-08-16 EP EP22162814.2A patent/EP4046991A1/en active Pending
- 2016-08-16 JP JP2016159454A patent/JP2017039714A/ja not_active Ceased
- 2016-08-16 AR ARP160102503A patent/AR105711A1/es unknown
-
2018
- 2018-01-24 PH PH12018500181A patent/PH12018500181A1/en unknown
- 2018-02-15 IL IL257559A patent/IL257559B/en unknown
- 2018-02-16 CL CL2018000430A patent/CL2018000430A1/es unknown
- 2018-02-19 ZA ZA2018/01134A patent/ZA201801134B/en unknown
- 2018-03-12 CO CONC2018/0002516A patent/CO2018002516A2/es unknown
-
2020
- 2020-03-03 US US16/807,719 patent/US20210024486A1/en not_active Abandoned
- 2020-09-04 JP JP2020148973A patent/JP2020193235A/ja not_active Ceased
-
2022
- 2022-08-12 JP JP2022128590A patent/JP2022163169A/ja active Pending
-
2023
- 2023-02-24 US US18/114,043 patent/US12492182B2/en active Active
- 2023-12-08 JP JP2023207429A patent/JP7640658B2/ja active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| JP2011525905A (ja) * | 2008-06-26 | 2011-09-29 | 田辺三菱製薬株式会社 | 神経変性疾患治療用のｇｓｋ３−ベータ阻害剤としての４−（ピリジン−４−イル）−１ｈ−（１，３，５）トリアジン−２−オン誘導体 |
| EP2383262A1 (en) * | 2008-12-10 | 2011-11-02 | Topharman Shanghai Co., Ltd. | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof |
| JP2012511517A (ja) * | 2008-12-10 | 2012-05-24 | 上海特化医薬科技有限公司 | フェニルピリミドン骨格を有する化合物、その薬剤組成物、その製造方法及び用途 |
| WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2015125842A1 (ja) * | 2014-02-20 | 2015-08-27 | 日本たばこ産業株式会社 | トリアジン化合物及びその医薬用途 |
| EP3109240A1 (en) * | 2014-02-20 | 2016-12-28 | Japan Tobacco, Inc. | Triazine compound and use thereof for medical purposes |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7640658B2 (ja) | ヒドロキシトリアジン化合物及びその医薬用途 | |
| CN105814067B (zh) | 作为钠通道调节剂的吡啶酮酰胺的前药 | |
| JP2021054856A (ja) | トリアジン化合物及びその医薬用途 | |
| CN105683157B (zh) | 用作钠通道调节剂的磺酰胺类 | |
| WO2022121805A1 (zh) | 作为Nav1.8抑制剂的并环化合物及其用途 | |
| CN116462662A (zh) | 芳香并环类Nav1.8抑制剂及其用途 | |
| CN103153996A (zh) | 作为激酶抑制剂的喹啉和喹喔啉衍生物 | |
| JP2022530405A (ja) | Ｎ－メチル－２－ピリドンを含む化合物、および薬学的に許容される塩 | |
| CN102421771B (zh) | 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2003514898A (ja) | Ｃｏｘ−２の選択的阻害剤としてのピリミジン誘導体 | |
| WO2025051180A1 (zh) | 内酰胺类衍生物及其应用 | |
| RU2772907C2 (ru) | Соединение гидрокситриазина и его применение в медицинских целях | |
| HK40079824A (en) | Hydroxytriazine compounds and pharmaceutical use thereof | |
| WO2020098658A1 (zh) | 20位取代的喜树碱衍生物及其制备方法和应用 | |
| HK1256768A1 (en) | Hydroxytriazine compound and medical use thereof | |
| RU2811402C2 (ru) | Пролекарства пиридонамидов, применяемые в качестве модуляторов натриевых каналов | |
| CN111566098A (zh) | 环状胺衍生物及其药物用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |